Table 2.
Obstetric and neonatal outcomesa
| Outcomes | Overall | Outcomes by subgroup
|
||
|---|---|---|---|---|
| MT 16 | CPM | P value | ||
| Obstetric | ||||
| Gestational hypertension or preeclampsia | 38.1% (16/42) | 36.7% (11/30) | 41.7% (5/12) | >0.99 |
| Gestational diabetes | 4.8% (2/42) | 6.7% (2/30) | 0.0% (0/12) | >0.99 |
| PPROM | 11.9% (5/42) | 16.7% (5/30) | 0.0% (0/12) | 0.30 |
| Preterm birth | 71.4% (30/42) | 70.0% (21/30) | 75.0% (9/12) | >0.99 |
| Cesarean delivery | 73.8% (31/42) | 70.0% (21/30) | 83.3% (10/12) | 0.46 |
|
| ||||
| Neonatal | ||||
| GA at delivery (weeks) | 34.0 (24.0–40.0) | 34.7 (28.1–40.0) | 33 (24.0–38.7) | 0.13 |
| Birth weight <10th percentile | 73.8% (31/42) | 76.7% (23/30) | 66.7% (8/12) | 0.44 |
| NICU admission | 88.1% (37/42) | 86.7% (26/30) | 91.7% (11/12) | >0.99 |
| Congenital anomalies | ||||
| Any anomaly | 59.5% (25/42) | 70.0% (21/30) | 33.3% (4/12) | 0.04 |
| ≥2 anomalies | 38.1% (16/42) | 46.7% (14/30) | 16.7% (2/12) | 0.09 |
| Ocular | 4.8% (2/42) | 3.3% (1/30) | 8.3% (1/12) | 0.50 |
| ENT | 7.1% (3/42) | 6.7% (2/30) | 8.3% (1/12) | >0.99 |
| Any cardiac | 57.1% (24/42) | 66.7% (20/30) | 33.3% (4/12) | 0.08 |
| CCHDc | 14.3% (6/42) | 20.0% (6/30) | 0.0% (0/12) | 0.16 |
| Pulmonary | 2.4% (1/42) | 3.3% (1/30) | 0.0% (0/12) | >0.99 |
| Gastrointestinal | 7.1% (3/42) | 10.0% (3/30) | 0.0% (0/12) | 0.55 |
| Genitourinary | 19.1% (8/42) | 23.3% (7/30) | 8.3% (1/12) | 0.40 |
| Musculoskeletal | 21.4% (9/42) | 30.0% (9/30) | 0.0% (0/12) | 0.04 |
| Central nervous system | 11.9% (5/42) | 16.7% (5/30) | 0.0% (0/12) | 0.30 |
Boldfaced values indicate comparisons reaching statistical significance.
Fisher’s exact test compared proportions between groups.
CCHD, critical congenital heart defect; CPM, confined placental mosaicism; ENT, ear, nose, and throat; GA, gestational age; MT 16, mosaic trisomy 16; PPROM, preterm premature rupture of membranes.
a
Median values with ranges are presented for continuous variables.